Ascites causes significant discomfort and has negative impact on patient's quality of life. Medical therapies including dietary restriction and diuretics are successful in only 40 to 44% of patients with malignant ascites and repeated paracentesis only provides temporary symptomatic relief. Therefore, a more permanent solution is necessary. Indwelling catheters or peritoneovenous shunt placement can provide more permanent symptomatic relief and improve patients' quality of life. Unlike indwelling catheters, peritoneovenous shunts do not limit patients' life style and therefore should be offered as first option in patients who are good candidates. Denver shunt (CareFusion-BD Worldwide) is the current available peritoneovenous shunt. In this article, the indications, contraindications, technical aspects of shunt placement, and techniques to prevent postprocedure complications will be discussed.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5730438 | PMC |
| http://dx.doi.org/10.1055/s-0037-1608705 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Refractory bilateral chylothorax and chylous ascites in a patient with systemic lupus erythematosus treated by pleuro-peritoneal and peritoneal-venous shunts along with cell-free and concentrated ascites re-infusion therapy.
Respir Investig
November 2024
Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, 5-1-1 Nabeshima, Saga, Saga Prefecture, 849-8501, Japan.
Article Synopsis
- - A pleural effusion is a common issue for patients with systemic lupus erythematosus (SLE) and requires careful diagnosis for proper treatment.
- - The case discusses a rare occurrence of chylothorax in an SLE patient, which can be tough to manage despite strong immunosuppressive treatments, often leading to poor health and malnutrition due to frequent procedures.
- - To improve breathing and prevent malnutrition, treatments like pleuro-peritoneal and peritoneal-venous shunts, along with specialized therapies, may be useful.
Drainage of ascites in cirrhosis.
World J Hepatol
September 2024
Department of Gastroenterology, Shenzhen People's Hospital, The Second Clinical Medical College, Jinan University, Shenzhen 518000, Guangdong Province, China.
Article Synopsis
- - For managing refractory ascites in cirrhosis, diuretics, albumin, and vasoactive drugs are commonly used first, but their effectiveness is often limited.
- - When medication fails, various drainage techniques, such as large-volume paracentesis and shunts, are considered to manage fluid buildup.
- - The review discusses the pros and cons of these drainage methods, including their specific use cases and when they might not be appropriate.
Intranodal Lymphangiography and Embolization for Management of Iatrogenic Chylous Ascites after Oncological Surgery.
J Vasc Interv Radiol
June 2024
Division of Interventional Radiology, Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, New York.
Purpose: To investigate the safety and effectiveness of intranodal lymphangiography (INL) and lymphatic embolization (LE) in management of chylous ascites after oncologic surgery.
Materials And Methods: Retrospective review of records of patients who underwent INL with or without LE from January 2017 to June 2022 was performed. Adult patients with chylous ascites after oncologic surgery referred to interventional radiology after failure of conservative treatment were included.
Chronological Course and Clinical Features after Denver Peritoneovenous Shunt Placement in Decompensated Liver Cirrhosis.
Tomography
March 2024
Department of Gastroenterology and Hepatology, Yokohama City University Graduate School of Medicine, Yokohama 236-0004, Japan.
Background: Refractory ascites affects the prognosis and quality of life in patients with liver cirrhosis. Peritoneovenous shunt (PVS) is a treatment procedure of palliative interventional radiology for refractory ascites. Although it is reportedly associated with serious complications (e.
View Article and Find Full Text PDF[Role of peritoneovenous shunt therapy in end-of-life care of refractory malignant ascites cases].
Nihon Shokakibyo Gakkai Zasshi
December 2023
Department of Digestive and General Surgery, Shimane University, Faculty of Medicine.
The short- and long-term outcomes of 34 patients with refractory malignant ascites who underwent peritoneovenous shunt (PVS) therapy were retrospectively reviewed. The primary disease was gastrointestinal cancer in 31 patients and gynecologic cancer in 3 patients. Regarding performance status, 21 patients had Eastern Cooperative Oncology Group Performance Status (PS) 2 and 13 patients were PS 3;thus, many were in a poor general condition.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!